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Expression of surface immunoglobulin appears critical for the
growth and survival of B-cell lymphomas. In follicular lym-
phoma, we found previously that the Ig variable (V) regions in
the B-cell receptor express a strikingly high incidence of N-gly-
cosylation sequons,NX(S/T). These potential glycosylation sites
are introducedby somaticmutation and are lymphoma-specific,
pointing to their involvement in tumor pathogenesis. Analysis
of the V region sugars from lymphoma-derived IgG/IgM reveals
that they are mostly oligomannose and, remarkably, are located
in the antigen-binding site, possibly precluding conventional
antigen binding. The Fc region contains complex glycans, con-
firming that the normal glycan processing pathway is intact.
Binding studies indicate that the oligomannose glycans occupy-
ing the V regions are accessible to mannose-binding lectin.
These findings suggest a potential contribution to lymphoma
pathogenesis involving antigen-independent interaction of sur-
face immunoglobulin of theB-cell receptorwithmannose-bind-
ing molecules of innate immunity in the germinal center.
Expression of sIg8 is critical for the survival of normal B-cells
in the periphery, even in the absence of antigen (1), indicating
that a stimulatory surface Ig-mediated signal, independent of
antigen, is required (2). The majority of malignancies derived
from mature human B-cells may also require such a signal,
since sIg-negative tumors are rare. In FL, sIg retention is
remarkable, since inmost tumors, one Ig allele is compromised
by the characteristic t(14;18) chromosomal translocation. (3, 4)
In terms of pathogenesis, the translocation that up-regulates
expression of the BCL-2 oncoprotein appears necessary, but
not sufficient, for tumor development, since it can also occur in
B-cells of healthy individuals (5). Other factors must be
required for survival in the hostile germinal center (GC), where
normal B-cells that fail to be selected by antigen usually die.
FL occurs in theGCof lymphnodes, where tumor cellsmain-
tainmany features of normal GCB-cells. A nodular or nodular/
diffuse growth pattern is characteristic, with conservation of
themicroenvironment of follicular dendritic cells and CD4T
cells. In normal B-cells, the Ig V region genes undergo somatic
mutation in the GC. B-cells expressing Ig sequences that can
bind antigen are rescued from the default death pathway, allow-
ing further differentiation and subsequent exit as plasma cells
or memory B-cells (6, 7). Somatic mutation is also activated in
FL cells, with evidence of ongoing mutational activity in tumor
clones (8). Although Ig expression is retained, it has been diffi-
cult to envisage a role for multiple potential antigens in sup-
porting the growth of neoplastic B-cells. Interestingly, we
observed a striking difference in the B-cell receptor of lym-
phoma cells as compared with normal B-cells, which might
provide an alternative stimulatory pathway. In normal B-cells,
N-glycosylation is mainly confined to conserved sites in the Ig
constant regions, although a few germ line encoded V regions
do carry potentialN-glycosylation sites. In FLIg, the number of
potential sites increases dramatically during the somatic muta-
tion process. By analyzing VH sequences, we previously found
that 55 of 70 (79%) cases of FL contained these sequons. Sites
were also present in VL (9). This high incidence has been con-
firmed in 24 of 24 cases (10). Since glycosylation sites do not
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accumulate significantly in somaticallymutated normal B-cells,
the positive selection of B-cells in FL that express B-cell recep-
tor containing N-linked glycans suggested a potential role for
the oligosaccharides in tumorigenesis.
Sites generated by somatic mutation are frequent and possi-
bly mandatory in FL, but they also exist in other GC-associated
lymphomas (11). The incidence of potential N-glycosylation
sites in endemic Burkitt’s lymphoma (BL) is high (82%),
although sporadic BL and diffuse large cell lymphoma have
lower levels, 43 and 41%, respectively (9), possibly reflecting the
known heterogeneity of these tumors. In contrast to GC-asso-
ciated B-cell malignancies, sites are found at insignificant levels
in chronic lymphocytic leukemia (CLL) and multiple myeloma
(9).
The process ofN-linked glycosylation is initiated in the ER by
the transfer of the dolichol phosphate oligosaccharide precur-
sor, N-acetylglucosamine2-mannose9-glucose3, to suitable
asparagine residues in the glycosylation sequons of nascent
proteins (12). Following the removal of glucose and mannose
residues, the fully folded protein is transported to the Golgi,
where enzymes further process the glycans to hybrid and com-
plex-type. The exact processing of the glycans depends on fac-
tors such as the cell in which the glycoprotein is expressed and
the three-dimensional structure of the protein around the gly-
cosylation site (13, 14). When enzyme access is restricted, oli-
gomannose sugars may not be fully processed.
We have now characterized the glycosylation of the Fab
region of FLIgs that results from somatic mutation and probed
the accessibility of the glycans to C-type lectins. We have ana-
lyzed V region-associated sugars in tumor-specific Ig derived
from six cases of FL. We focused first on IgG-expressing cases,
since there are no conserved sites in the IgG Fab constant
regions, analyzing heavy chain (HC), light chain (LC), and Fab
fragments. Interestingly, the Fab glycans are mostly unproc-
essed oligomannose. FLIgM HC, which has a conserved glyco-
sylation site in the constant region at Asn171 occupied by com-
plex glycans, was also analyzed and showed a significant
increase in oligomannose sugars when compared with normal
human serum IgM (NIgM) (15, 16).
Studies with MBL, a C-type lectin, with both immobilized
FLIgG and sIg, which is part of the B-cell receptor, have
revealed that the terminal mannose residues on the Fab glycans
are accessible for binding. Molecular modeling based on amino
acid substitution of the Fab region has been used to ascertain
the location of N-linked glycosylation sites.
EXPERIMENTAL PROCEDURES
Idiotypic Ig Production and Identification of Tumor-derived
Gene Sequences—Six patients with Stage IVA FL had surgical
biopsy at first relapse following chemotherapy; five expressed
sIgG, and one expressed sIgM. The control patient had IgG
CLL, which expressed IgG without a potential V region N-gly-
cosylation site. Ig protein was generated from tumor cells iso-
lated from blood by producing heterohybridomas with the
K6H6/B5 cell line (ATCC: CRL1823) as previously described
(17–19). Resulting hybridomas were screened by enzyme-
linked immunosorbent assay for the production of Ig matching
the isotype of the tumor. The identities of fusions and tumor
were determined by comparing Ig VH CDR3 sequences. Ig was
purified from culture supernatants by affinity chromatography
(IgG, Protein A (Amersham Biosciences); IgM, anti-IgM anti-
body columns). Protein purity was determined by SDS-PAGE
electrophoresis and in each casewas95%.All Ig proteinswere
adjusted to a final concentration of 1 mg/ml. VH and VL gene
sequences were determined as previously described (9).
N-linkedGlycanAnalysis—15g of five FLIgG samples (FL2,
-4, -11, -31, and -32), one FLIgM (FL3), CLL1, normal human
serum NIgG, and NIgM were run on 10% SDS-polyacrylamide
gels (20, 21).HCandLCprotein bandsmigratingwith an appar-
ent molecular mass of 53–58 and 24–30 kDa, respectively, for
IgG and 75–90 and 29 kDa, respectively, for IgM were excised,
cut into1 mm3, frozen for2 h at20 °C, and washed with
alternating 1 ml of acetonitrile and 1 ml of 20 mMNaHCO3 pH
7 (five washes, 30 min each).N-Linked glycans were released in
situwith peptide-N-glycanase F (PNGase F; RocheApplied Sci-
ence) (20). The extracted glycans were labeled with the fluoro-
phore 2-aminobenzamide (2AB; Ludger Ltd., Oxford, UK) (22)
and processed through normal phase (NP) HPLC (23). Neutral,
monosialylated, and disialylated fractions were also collected
from weak anion exchange HPLC and processed by NP-HPLC
for further analysis and confirmation of NIgG, FL2, NIgM, and
FL3 peak assignments.
Exoglycosidase digestions were carried out on 2AB-labeled
glycan pools of N-linked glycans (23). Matrix-assisted laser de-
sorption ionization time-of-flight (MALDI-TOF) mass spectra
of unlabeled glycans were recorded as described previously
(20).
Papain Digestion of IgG and Fab/Fc Separation—Digestion
of IgG samples FL2, FL4, FL31, and NIgG (100 g) was per-
formedwith 1g of papain (Sigma) in 250l of 0.1 M phosphate
buffer containing 2 mM EDTA, 12 mM cysteine (pH 7) for 16 h.
To test the completion of the digestion, aliquots (4 l) were
treated with 50 mM iodoacetamide at 4 °C for 30 min to inacti-
vate papain, added to nonreducing SDS-sample buffer pre-
heated to 100 °C, and heated at 100 °C for 3 min. The samples
were analyzed by 8.5% SDS-PAGE. The papain digests were
dialyzed against 0.01 M phosphate buffer (pH 8) overnight and
applied to DEAE-cellulose (Whatman, Kent, UK) that was
equilibrated with the same buffer and packed into microcol-
umns (100–150-l bed volume). Undigested IgG, Fab, and
papain were eluted in flow-through fractions. Fc was eluted
with phosphate-buffered saline, pH 7.4. The separation of Fab
and Fc was confirmed by Western blotting using horseradish
peroxidase-conjugated versions of goat anti-human  chains,
goat anti-human  chains, and mouse anti-human IgG-Fc
(Serotec). Glycans from Fab and Fc fractions were released
from in-gel bands and analyzed.
PNGase F Digestion in Solution of FL2 Fab—8 l of FL2 Fab
were treated as above to inactivate the papain. 4 l were incu-
bated with PNGase F in solution for 36 h (24). The nonreduced
sample was run on 8.5% SDS-PAGE together with an undi-
gested aliquot.
MBL Purification and Binding Assay—Rabbit anti-MBL
polyclonal antiserum was depleted of any anti-mannan anti-
bodies on a mannan-agarose resin (catalog number M9917;
Sigma) and then pre-equilibrated in phosphate-buffered saline,
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0.5 mM EDTA (25). Purification was carried out as described
previously (25, 26). MBL concentration was calculated using a
standardized MBL detection enzyme-linked immunosorbent
assay using mannan capture. Enzyme-linked immunosorbent
assay plate (NUNC-Maxisorp) wells were coated with 100l of
10 g/ml FLIgG. CLL1 was used as a negative control. The
binding assay was performed as described previously (25).
Preparation of MBL Biotinylated with NHS-Biotin Bound to
Streptavadin-FITC—PurifiedMBL (500 g) in 10 mMHepes, 1
M NaCl, 5 mM EDTA, pH 7.4, was made up to 20mMCaCl2 and
concentrated on a 0.5ml columnof D-mannose immobilized on
cross-linked 4% beaded agarose (catalog number M-6400;
Sigma) which was washed with 50mMHepes, 150mMNaCl, 10
mMCaCl2, pH 7.5. MBL was eluted with 50 mMHepes, 150 mM
NaCl, 2.5 mM EDTA, pH 7.5, and 200-l fractions were col-
lected. TheMBL-containing fractions (400l) were made up
to 500l with wash buffer and incubated on ice for 30min with
a 25-fold molar excess over MBL (molecular mass taken as 300
kDa) of biotin 3-sulfo-N-hydroxysuccinimide ester (Sigma),
from 1 mg/ml stock freshly made up in wash buffer. The reac-
tion was stopped by adding 100 l of 1 M Tris, pH 7.8, and
incubating on ice for 10min. Thematerial was run as before on
0.5 ml of mannose-agarose resin. Eluted MBL was cross-linked
using 1.3 l of streptavidin-FITC (1 mg/ml, 60 kDa) (Sigma) to
50 g of biotinylated MBL (4-fold molar excess), allowing 2-h
intervals at 4 °C in the dark between each streptavidin-FITC
addition.
MBL Cell Binding Assay—A telomerase-immortalized
humanHK cell line, derived from a follicular dendritic cell, and
the EBV-ve BL cell line L3055were obtained fromDr. Y. S. Choi
(Cellular Immunology, Ochsner Clinic Foundation, New Orle-
ans, LA). L3055 cells that express surface IgM with a known
N-glycosylation site (27) were grown on HK feeder cells as pre-
viously described (28). After overnight incubation ofHK cells at
5  105/well (in 3 ml of Iscove’s modified Dulbecco’s medium
with 10% fetal calf serum, 1 mM pyruvate, 2 mM glutamine,
nonessential amino acids, 20 units/ml penicillin, and 20 g/ml
streptomycin, all from Invitrogen), 7  104 L3055 cells were
added per well and harvested after 2–3 days of incubation. BL-2
is an EBV-ve BL cell line (gift fromDr. A. Rickinson, University
of BirminghamMedical School, Birmingham, UK). It expresses
surface IgMwith noN-glycosylation sites (27). BL-2 cells were
grown as previously described (27, 28).
For each assay, 1 106 cells (L3055 or BL-2) were pelleted in
5-ml fluorescence-activated cell sorting tubes (1500 rpm, 5
min, 4 °C). Cells were resuspended in 500 l of either HBSS
(Sigma) supplemented with 5 mM CaCl2 or 5 mM EDTA to
demonstrate Ca2-dependent binding. The cells were centri-
fuged as before and resuspended in 250l of appropriate buffer
and incubated with 5 g (20 g/ml) of FITC-conjugated MBL
or 5g of goat anti-human IgM ( chain-specific) for 30min on
ice prior to analysis on a BD Biosciences FACSCalibur. The
effect of apoptosis on MBL binding to L3055 cells was investi-
gated by dual staining with MBL-FITC followed by Annexin
V-PE (BD Biosciences) according to the manufacturer’s
protocol.
L3055 and BL-2 cells were labeled with mouse anti-human
Ig FITC (BD Biosciences) and analyzed by fluorescence-acti-
vated cell sorting to determine surface immunoglobulin
expression. To mediate endocytosis of sIg, L3055 cells were
incubated overnight at 37 °C with goat F(ab)2 anti-IgM (
chain-specific) (Southern Biotech) at 10 g/ml. Loss of sIg was
monitored by staining with anti-human Ig FITC, and the cells
were then tested for MBL binding.
MolecularModeling—Molecularmodelingwas performed as
described previously (25). Briefly, sequence alignment was per-
formed using Align (29) on the equivalent domains of IgG
(Swiss-Prot: P01857) together with appropriate amino acid
substitutions. Crystal structures used as the basis of the model-
ing were obtained from the Protein Data Bank (30). The struc-
ture of FL2 was based on the crystal structure of murine N1G9
antibody (31). Themodels of FL3, FL4, and FL31 were based on
the crystal structure of the Fab domain of the monoclonal anti-
body againstHIV-1GP41 (32).N-Glycanswere generated using
the data base of glycosidic linkage conformations and in vacuo
(33, 34) energy minimization to relieve unfavorable steric
interactions.
RESULTS
V Gene Analysis—Analysis of gene segment sequences
encoding V regions of FL cases (Table 1) show that a range of
VH and VL genes were used, all of which were somatically
mutated. In all cases, potential N-glycosylation sites NX(S/T)
were identified. All contained sites in VH; FL32 (IgG) and FL3
(IgM) each had an additional site in VL. The position of sites
varied; FL2 contained two in CDRH2, at Asn52 and Asn52c, and
TABLE 1
HC and LC gene segment usage and glycosylation sites
V(D)J gene segment usage was determined by aligning nucleotide sequences to germ line sequences in V-BASE using MacVector 6.5.3 sequence analysis software
(Accelerys, Cambridge, UK). D gene segments could not be assigned due to insufficient homology.
Case Ig VH JH Percentage homology VL JL Percentage homology No. of sites/region Sequence
% %
FL2 IgG 3–21 6 90.2 1e 2/3 92.8 2/CDRH2 INGSN
SNTSS
1/CDRH3 RNCSS
FL4 IgG 1–18 6 90.5 1b 2/3 94.0 1/CDRH3 RNSSS
FL11 IgG 3–72 6 86.4 1b 2/3 88.0 1/CDRH3 SNCSR
FL31 IgG 3–30 6 90.5 1b 1 97.0 1/CDRH3 KNETW
FL32 IgG 4–39 5 88.8 1e 2/3 95.2 1/CDRH2 GNISS
1/CDRL2 YNSSN
FL3 IgM 4–59 2 85.6 2e 2/3 94.9 1/FRH1 LNCTV
1/CDRH2 GNISS
1/FRL4 TNLTV
CLL1 IgG 3–73 93.3 A19 98.0
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one in CDRH3 at Asn95. In FL2, both CDRH2 sites resulted
from codon insertions, with aGly residue inserted betweenAsn
and Ser and an Asn residue inserted prior to TS. The other four
patient IgG samples each had a single site in VH: FL4 at Asn95,
FL11 at Asn96, FL31 at Asn95, all in CDRH3, and FL32 at Asn50
in CDRH2. FL32 also had a potential site in VLwithinCDRL2 at
Asn50. FL3 had two potential sites at Asn21 in framework region
H1 and Asn50 in CDRH2 and a potential site in VL within
framework region L4 at Asn103. The Ig derived from CLL1 as a
hybridoma control had none.
N-linked Glycan Analysis—Ig secreted by tumor-derived
heterohybridoma cells was run on 10% SDS-polyacrylamide
gels under reducing conditions. Five patient-derived IgG sam-
ples and one IgM sample were analyzed together with three
controls, CLL1, NIgG, and NIgM. The gel (Fig. 1a) shows that
the HC of CLL1 and NIgG migrated with an apparent molecu-
lar mass of 55 kDa, whereas all of the patient samples were58
kDa, which is consistent with the glycosylation of the Fab
region. Glycosylation was also indicated for FL3 HC, since it
migrated with an apparent molecular mass of 90 kDa (Fig. 1b),
whereas NIgM HC migrated at 75 kDa. The LC of FLIgG
migrated between 24 and 30 kDa. The LC of both NIgM and
FL3 had an apparent molecular mass of 29 kDa, suggesting a
lack of glycosylation of the FL3 LC although it has a potential
site.
Complete NP-HPLC glycan pro-
files were obtained for the 2AB-la-
beled HC glycans of all patient-de-
rived samples and controls (Fig. 1, c
and d). The system was calibrated
using an external standard of hydro-
lyzed and 2AB-labeled glucose oli-
gomers to create a standard curve.
The retention times for the individ-
ual glycans were converted to glu-
cose unit (GU) values using this
curve. Preliminary peak assign-
ments were made by comparing the
GU values with theOxfordGlycobi-
ology data base of experimental val-
ues, and the assignments were con-
firmed by exoglycosidase array
digestions (23). These were carried
out to remove the monosaccharides
sequentially to elucidate the struc-
tures. Weak anion exchange HPLC
data were used to facilitate the
assignments of neutral and sialy-
lated peaks of FL2 that coeluted
(data not shown). All of the FLIgG
samples contained the characteris-
tic profile of complex glycans seen
in NIgG (peaks 3, 11, 12, 20; Table 2
and supplemental Table S1), but
there was unexpectedly also an oli-
gomannose (M) series, M5–M9
(peaks 5, 15, 24, 31, and 36), with
both types of glycan in varying pro-
portions (Fig. 1, Table 2, and supplemental Table S1). The com-
plex glycans were consistent with previous analyses of serum
IgG Fc (35, 36), confirming that the normal glycan processing
pathway was intact. CLL1 showed a characteristic IgG HC gly-
can NP-HPLC profile with 30% fucosylated (F; for assignment
nomenclature, see Tables 2 and 3), agalactosylated, and
monogalactosylated (G1) glycans with only 1% sialylation (S)
but lacking glycans with bisecting (B) GlcNAc seen in human
NIgG, marked with an asterisk in Fig. 1c. Structural represen-
tations of the biantennary (A2) glycan FA2BG1 and M6 are
shown in Fig. 1e. A small percentage (3%) of glycans termi-
nating in -galactose (Ga) was also found (Table 2 and supple-
mental Table S1). The presence of-galactose (peaks 24, 27, 32,
35, 36, and 41) and the absence of bisected glycans in both
control and patient samples indicated that the mouse glycosy-
lation machinery is operative in all of these heterohybridomas,
as shown elsewhere (37). The presence of M5–M9 suggested
that these glycans were in positions inaccessible to mannosi-
dase I and GlcNAc transferase I, the actions of which are
required prior to processing to complex-type sugars. Together
with the oligomannose-type, FL2 contained higher molecular
mass glycans (e.g. biantennary structures, FA2G2S2 (7%), and
FA2G2Ga1S2 (1%)) either absent in the other samples and con-
trols or present in very small quantities (1%) (Fig. 1c, Table 2,
and supplemental Table S1). The production ofmore processed
FIGURE 1. Gels and NP-HPLC glycan profiles of FLIgs. a and b, 10% SDS-polyacrylamide gels run under
reducing conditions. An increase in molecular mass of FL HC bands is evident when compared with controls,
which is indicative of glycosylation. c, profiles of FLIgG HC and two controls. Glycans contained in the two
controls, CLL1 andNIgG, are evident in the FLIgG samples, interspersedwith oligomannose,M5–M9. d, profiles
of FLIgM (FL3) together with NIgM. Major peaks are named or numbered (Tables 2 and 3). *, peak containing
bisected structure, FA2BG1, present in human IgGbut not inmouseglycans. e, structural representations ofM6
and FA2BG1. Open circle, mannose; filled square, GlcNAc; open diamond, galactose; open diamond with dot,
fucose; M, mannose; F, 1–6 core fucose; A, antennary; B, bisected; G, galactose. Linkage is indicated by the
angle linking adjacent residues. , 1–2; ⁄, 1–3; –, 1–4; , 1–6; dotted line,  linkage; solid line,  linkage;
, unknown linkage. The NP-HPLC system was calibrated using an external standard of hydrolyzed and 2AB-
labeled glucose oligomers to provide a dextran ladder from which the retention times for the individual
glycans were converted to GU. These were comparedwith the Glycobiology Institute data base of experimen-
tal values to obtain preliminary assignments for the glycans that were confirmed by digestions with arrays of
exoglycosidases and mass spectrometry.
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glycans is consistent with the more usual pattern of glycosyla-
tion that occurs in the 10% of NIgG Fab where there is an
N-glycosylation site due to somatic mutation that is fully acces-
sible (38, 39).
FL32 has a potential N-glycosylation site on the LC, but no
glycans were recovered. Molecular modeling showed that the
site is on an exposed loop close to the VH/VL interface. Glyco-
sylation could interfere with the assembly of the IgG, leading to
the secretion of nonglycosylated isoforms only. None of the
other IgG LCs had potential glycosylation sites.
The glycans of NIgM (Table 3 and supplemental Table S2)
were consistent with previous analyses (16). NIgM has five gly-
cosylation sites on the HC (Asn171, Asn332, Asn395, Asn402, and
Asn563). Oligomannose glycans occupy conserved sites at
Asn402 and Asn563 (15, 40). In this study, 31% of the glycans
from NIgM were oligomannose. This is consistent with 100%
occupancy of Asn402, which is homologous with Asn297 of IgG
and is always fully occupied, and50% occupancy of Asn563. It
has been shown previously (16) that the oligomannose glycans
in these conserved sites are not accessible for MBL binding.
Two further NIgM samples had 28 and 30% oligomannose gly-
cans (data not shown). FL3 (Fig. 1d, Table 3, and supplemental
Table S2) showed an increase to 49% oligomannose glycans,
which is consistent with the occupancy of one of the two addi-
tional N-glycosylation sites in the Fab with oligomannose. The
NP-HPLC profile shows that 9% of the glycans had a molecular
mass higher than those of NIgM, including triantennary (A3)
trisialylated (S3) structures (Table 3 and supplemental Table
S2, peaks 42–46). The potential site on the LC contained oligo-
mannose glycans, 80% M6 and 20% M5 (data not shown).
Structural representations of all of the glycans from Tables 2
and 3 are shown in supplemental Table S3.
Jack Bean -Mannosidase Digestions—The glycan pool of
FL31 HC (Fig. 2a, Table 2, and supplemental Table S1) is rep-
resentative of three other samples (FL4, -11, and -32). Jack bean
-mannosidase digestion of FL31 and FL2 glycans (Fig. 2, b and
d) confirmed the presence of oligomannose glycans, and the
profile remaining after removal of the mannose glycans was
very similar to that of CLL1 (Fig. 1c). There are additional gly-
cans (3%) in the FL2profile (Fig. 2d) that are hybrid structures
(Peaks 17 and 22 and included in peaks 5, 15, and 24; Fig. 2c,
Table 2, and supplemental Table S1) in which mannose resi-
dues on the 6 arm of the trimannosyl core that were not pro-
cessed by the glycosylation pathway enzymes have been
digested. Structural representations of M5 and M7–M9 are
included in Fig. 2. The presence of oligomannose glycans in FL3
TABLE 2
Peak assignments and percentage abundance of glycans of NIgG and FLIgGs
Peak number Assignmentsa NIgGb CLL1b FL2b FL4b FL11b FL31b FL32b
% % % % % % %
1 A2 1 2 7 3 1
2 A2B 1
3 FA2 17 14 3 8 35 11 8
5 M5 17 3 8 3 2
FA1G1 1
FA2B 5
6 A2G1(6) 1 3 1 2 1 3 1
8 A2G1(3) 1 5 1 3 2 1 1
9 A2BG1(6) 1
11 FA2G1(6) 18 24 4 16 15 15 18
12 FA2G1(3) 9 6 2 7 4 4 3
13 FA2BG1(6) 5
14 FA2BG1(3) 1
15 M6 3 25 16 32 35
FM5A1 1
16 A2G2 1 5 2 2 2
17 FA1G1S1 1
18 A2BG2 1
19 A2G1S1 1 2 1 1 1 1 1
20 FA2G2 19 26 5 14 3 5 16
21 FA2BG2 4
22 M5A1G1 1
23 FA2G1S1 1 1 1 2 2 1 1
24 FA3G2 6
M7 2 7 10 2
FM5A1G1
A2G2Ga1
25 A2G2S1 2 2 1 1 1
27 FA2G2Ga1 3 3 2 1 1 3
28 FA3G3 1
29 FA2G2S1 11 7 12 7 1 2 2
30 FA2BG2S1 3
31 M8 1 1 2 7 4
32 A2G2Ga1S1 2 1 1
34 A2G2S2 2 1 1 1 1
35 FA2G2Ga1S1 4 1 1
36 M9 20 1 1 2
FA2G2Ga2
38 FA2G2S2 2 1 7 1 1
39 A2BG2S2 2
41 FA2G2Ga1S2 1 1
a A, antennary (followed by number of N-acetylglucosamine (GlcNAc) residues); A2, biantennary; B, bisect; F,  1–6-linked core fucose; G,  -galactose; Ga,  -galactose; M,
mannose; S, sialic acid; (3) or (6), linkage of G to GlcNAc on 3 or 6 arm of trimannosyl core, respectively.
b Percentage determined from NP-HPLC areas.
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(Fig. 2e) was also confirmed. Again, there are additional struc-
tures from digested hybrid glycans (Fig. 2f). Details of GU val-
ues, peak areas, and mass spectrometry of both FLIgM and
NIgM are shown in Table 3 and supplemental Table S2.
Papain Digestion of IgG—In order to confirm the location
of the oligomannose glycans, the Fab and Fc regions were
cleaved by papain digestion. The HC of NIgG was also
digested by papain. Fractions containing Fab and Fc were
confirmed byWestern blotting (Fig. 3, a, b, c, and d). Fab and
Fc fractions of NIgG, FL2, and FL4 were separated by DEAE.
Separation of the corresponding fractions of FL31 was
achieved by SDS-PAGE alone (Fig. 3c). FL2 Fab, which
migrated as three bands (Fig. 3d), was digested by PNGase F
in solution. The three bands collapsed into two, x and y (Fig.
3e). Glycan analysis of these bands showed that the protein
in the major band ywas not glycosylated, and the minor band
x contained only M9 caused by incomplete digestion (data
not shown). Variable occupancy of the three N-linked glyco-
sylation sites was therefore confirmed.
Glycan Analysis of Fab and Fc Fractions—The Fab was
shown to be glycosylatedwith oligomannose in three cases (Fig.
4), whereas the corresponding Fc contained only complex gly-
cans. This, together with the position of the N-linked sequons,
clearly locates the oligomannose glycans in the V region and
also demonstrates the ability of the glycosyl transferases to
FIGURE 2.NP-HPLC profiles of FLIg with jack bean-mannosidase diges-
tions. FL31 (a), FL2 (c), and FL3 (e) are undigested glycan pools together with
b, d, and f, which are jack bean -mannosidase digestions. Oligomannose
peaks are labeled. The removal of these peaks confirms the presence of oli-
gomannoseglycans and reveals thepresenceof complexglycans andprofiles
that correlate with normal controls. In the profiles of both FL2 and FL3, there
is also evidenceof hybrid structures inwhichmannose residues, on the6 arm
of the trimannosyl core that were not processed by glycosylation pathway
enzymes, have been digested. There are structural representations ofM5 and
M7–M9 (as described in the legend to Fig. 1).
FIGURE 3. Glycoprotein staining andWestern blot analysis of Fab and Fc frac-
tions (a–d). 8.5% SDS-polyacrylamide gels and Western blots of Fab and Fc
fractions of NIgG, FL4, FL31, and FL2. Fab and Fc fractionswere obtained after
DEAE chromatography of NIgG, FL4, and FL2 following papain digestion of
FLIgG samples. Lanes a, flow-through fractions; lanes b, eluate. Separation of
FL31 (c) was achieved by gel electrophoresis alone. FL4 and FL31 contained
single bands of Fab, whereas FL2 (d) contained three, labeled 1–3. e, FL2 Fab
was treated with PNGase F in solution. The gel shows two bands. Following
glycan analysis, x was shown to contain M9 due to incomplete deglycosyla-
tion, whereas ywas completely deglycosylated.
TABLE 3
Peak assignments and percentage abundance of glycans of NIgM
and FLIgM
Peak number Assignmenta NIgMb FL3b
% %
1 A2 1
2 A2B 1
3 FA2 1
4 A1G1 1
5 M5 24 7
7 FA1G1 1 1
10 M4A1G1 2 2
13 FA2BG1 4
15 M6 4 26
16 A2G2 1
17 FA1G1S1(6) 2 1
20 FA2G2 4 2
A3G2 4
A2G1S1(6) 4 1
21 FA3G2/FA2BG2 7
22 M5A1G1 1
23 M4A1G1S1(6) 4
FA2G1S1(6)
24 M7 3 9
25 A2G2S1(6) 3 4
26 A2BG2S1 1
29 FA2G2S1(6) 17 9
30 FA2BG2S1 21
31 M8 5
32 A2G2Ga1S1(6) 1
33 FA3G2S1(6) 1
34 A2G2S2(6) 1
35 FA2G2Ga1S1(6) 7
36 M9 2
37 FA3G3S1(6) 1
38 FA2G2S2(6,6) 4 9
FA2G2S2(3,6) 4 9
40 FA2BG2S2(6,6) 5
FA2BG2S2(3,6) 5
42 FA3G3Ga1S1(6) 2
A3G3S2(6,6) 2
FA3G3S2(3,6) 2
FA3G3S2(6,6) 2
43 FA3G3S2(3,3) 2
FA3G3Ga1S2(6,6) 2
44 FA3G3S3(3,3,6) 1
45 FA3G3S3(3,6,6) 3
46 FA3G3S3(6,6,6) 1
a A, antennary (followed by number ofN-acetylglucosamine residues); A2, bianten-
nary; B, bisect; F,  1–6-linked core fucose; G,  -galactose; Ga,  -galactose; M,
mannose; S, sialic acid; (3) or (6), 2–3- or 2–6-linked sialic acid.
b Percentage determined from NP-HPLC areas.
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process complex glycans in the Fc regions. Although FL4 and
FL31 appeared to contain only oligomannose glycans (Fig. 4, a
and b), the three bands of FL2 Fab contained both oligoman-
nose and complex glycans (Fig. 4d). The high proportion
(69%) of oligomannose glycans from the fully occupied Fab1
indicates that mannosidase I and GlcNAc transferase I have
restricted access to two of the sites. Half of the31% complex
glycans consisted of triantennary and biantennary structures
with the addition of -galactose plus mono- and disialylation.
This compares with no triantennary structures and 5% disialy-
lation of the Fc, confirming that the third glycosylation site is
more accessible than the Fc to the glycosylation pathway
enzymes. The mixture of oligomannose and complex glycans
on Fab2 and -3 bands, 59 and 71% oligomannose, respec-
tively, indicates that there may not have been complete separa-
tion of the two bands by SDS-PAGE. The 59% of oligoman-
nose of Fab2 suggests that the two sites are occupied by one
oligomannose and one complex/hybrid-type glycan (38/3%,
respectively). About 10% of the Fab of NIgG HC contained
complex structures, including glycans ofmolecularmass higher
than those on the Fc, as has been shown previously (data not
shown) (39). The two other papain-digested samples, FL4 and
FL31, had 73% (63% M6) and 88% (56% M6) oligomannose
glycans, respectively, with a small percentage of complex gly-
cans. With FL4, these could be from small quantities of Fc that
were not completely retained by DEAE-cellulose chromatogra-
phy. With FL31, complete separation was achieved by SDS-
PAGE, indicating that 10% of the glycans were processed to
complex glycans. These data are consistent with one glycosyla-
tion site in the Fab region. Analysis of the Fc regions (Fig. 4,
a–c) also revealed some differences between the samples. FL2
and FL4 have similar quantities of asialylated, agalactosylated
(14%), andmonogalactosylated (30%) structures, whereas FL31
contains 27 and 45% respectively. A reduction in galactosyla-
tion is known to be related to age and to some diseases, in
particular rheumatoid arthritis and Crohn disease (41, 42). FL2
has 32%monosialylated structures with and without core fuco-
sylation, whereas FL4 and FL31 have 21 and 11%, respectively.
This demonstrates some differences in the activities of galacto-
syl and sialyl transferases of the individual tumor-derived het-
erohybridoma cell lines.
IgG Fab has N-glycosylation sites acquired only through
somatic mutation, whereas IgM Fab has a conserved N-glyco-
sylation site at Asn171, occupied by complex glycans (43), in the
CH region as well as the possibility of sites acquired through
somatic mutation. The glycan pool released from FLIgM Fab
would therefore include glycans from both regions. The contri-
bution from glycosylation resulting from somatic mutation in
FLIgMwas elucidated by comparing the percentage changes of
the total glycan pool with those from NIgM.
MBL Binding Assay—MBL bound to all three FLIgGs tested,
confirming that the terminal mannose residues were accessible
to the lectin. Mannan and CLL1 were used as positive and neg-
ative binding controls, respectively. Protein concentrations for
the Igs were normalized toCLL1 to account forMBL binding to
any terminal GlcNAc present in the Fc (44). The graph in Fig. 5
shows that MBL binds most strongly to FL2, which has three
glycosylation sites, two of which are occupied by oligomannose
glycans. The binding is approximately twice that of the other
two samples, which correlateswith the singlemannosylated site
in the Fab of FL11 and FL31.
Binding of MBL to sIgM—To assess specific binding of MBL
to cell surface Ig, two Burkitt’s lymphoma cell lines were used.
Motifs similar to those in FL have been found in these GC-
associated B-cell tumors. FL cell lines were not used, since they
are not as well characterized, and there would be no negative
control. Two parallel Epstein-Barr virus-negative cell lines,
each derived from sporadic BL and expressing comparable lev-
els of sIgM, were analyzed (Fig. 6, a and b). In both cases, VH4
gene segments were used to encode Ig VH, but L3055 carries an
N-linked glycosylation site in CDR2, whereas BL-2 has nomotif
(27). No sites were found in either of the VL sequences. L3055
FIGURE 4.NP-HPLCglycanprofiles ofHC, Fab, andFc fractions. FL4 (a) and
FL31 (b) showHC glycosylation together with Fc and Fab, demonstrating the
presence of oligomannose on the Fab fragments only. c and d show the chro-
matograms of FL2 glycans with the Fc without oligomannose plus three gly-
cosylated Fab bands. The combination of complex and oligomannose gly-
cans in Fab2 and -3 indicates that there may not have been complete
separation of the two bands by SDS-PAGE.
FIGURE 5.MBL binding to three FLIgG samples, FL2, FL11, and FL31.MBL
binding to FLIgG immobilized on microtiter plates was assessed. Binding to
FL2 is approximately twice that of the other two samples. FL2 has two
N-linked glycosylation sites in the antigen-binding region; FL11 and FL31
each have a single N-linked glycosylation site. CLL1 is a negative control. The
bars show themean binding 1 S.D. Mannan was used as a positive control.
The mean binding less the EDTA control was 3.783  0.094 S.D. (data not
shown).
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cells were able to bind to biotinylatedMBL preconjugated with
streptavidin-FITC, and this was ablated by removal of Ca2
(Fig. 6a). In contrast, BL-2 cells showed only marginal binding
of MBL, not significantly affected by removal of Ca2 (Fig. 6b).
This confirms that the oligomannose glycans in the conserved
sites were not accessible for binding. Although viability was
90% and only viable cells were analyzed, L3055 cells tend to
undergo apoptosis upon removal from HK cells (28). It was
important, therefore, to assess any effects of early apoptosis on
binding of MBL. Annexin V-positive and annexin V-negative
L3055 cells showed similar binding to MBL, indicating no sig-
nificant influence of apoptosis on binding (data not shown).
To correlate binding of MBL by L3055 cells with expres-
sion of sIgM, cells were treated with goat F(ab)2 anti-human
IgM ( chain-specific) overnight in order to reduce surface
expression by endocytosis. On gated live cells, there was a
reduction in the expression of sIgM following endocytosis
(Fig. 6c) as compared with the control (Fig. 6a). This was
mirrored by a significant loss of ability to bind MBL, which
became comparable with the low level of binding in the
absence of Ca2 (Fig. 6c). These data locate the binding of
MBL to sIgM and strongly indicate that the glycosylation site
in the Fab is critical for binding.
Molecular Modeling—Molecular
modeling of the V regions of the
Fabs of FL31 (Fig. 7) and FL4 (data
not shown) has shown that the Fab
glycosylation site (Asn95 in both
cases) is in the antigen-binding
groove. FL2 has two glycosylation
sites (Asn52 and Asn95) in the anti-
gen-binding groove and one
(Asn52c) that is on an exposed loop
(data not shown). The FL3 glycosy-
lation site in the CDRH2 region
(Asn50) is also in the antigen-bind-
ing groove (data not shown). The
model (Fig. 7) demonstrates that it
is structurally feasible to have a typ-
ically folded Fab domain with gly-
cans present at the site in the anti-
gen-binding groove. Detailed
examination of the model indicates
that the diequatorial hydroxyl
groups on C3 and C4 of terminal
mannose residues are accessible,
consistent with the experimental
data that demonstrates the recogni-
tion of the glycans by MBL. How-
ever, access to the nonterminal gly-
can residues appears to be restricted
by the location of the glycosylation
sites in the antigen-binding groove
and by the relatively long CDR
loops, consistent with the observed
lack of processing of these glycans
by mannosidase I and GlcNAc
transferase I. A Man6GlcNAc2 gly-
can was modeled on to the protein, since this was the most
abundant glycan identifed in the FL31 Fab.
DISCUSSION
Tumor cells in the majority (85%) of FL cases carry N-gly-
cosylation sites in theCDRs (9, 10), and these cells are positively
selected and functional (9). We have established the location
and structures of the oligosaccharides attached to the V region
of FLIg and their binding to the C-type lectin MBL and discuss
their possible role in B-cell proliferation. Although most of the
data in this paper are derived from protein secreted by hetero-
hybridomas established from lymphoma cells, the evidence
from the unmanipulated BL cell line points to a comparable
expression of surface IgM with characteristics similar to those
of FLIg.
V region glycans of sIgG and sIgM from FL tumor cells have
been shown to be mostly oligomannose; in contrast, the Fc
regions of the same molecules contain processed complex gly-
cans, confirming that the normal glycan processing pathway is
intact. In all of the FL cases, there is a high proportion of oligo-
mannose, indicating an inaccessibility of these glycans to man-
nosidase I, which trims back the 1–2-linked mannose sugars,
and to GlcNAc transferase I, which puts on the first GlcNAc
FIGURE 6. Surface IgM expressed by L3055 cells binds to MBL. L3055 cells (glycosylation site in VH) (a) and
control BL-2 cells (noglycosylation site inVHorVL) (b) expressed similar levels of sIg (thin lines). Each cell linewas
incubated with biotinylated MBL preconjugated with streptavidin-FITC in the presence or absence of Ca2.
a, L3055 cells boundMBL (thick line), and binding was ablated in the absence of Ca2 (dotted gray line). b, BL-2
cells bound very low levels of MBL (thick line), which was slightly reduced in the absence of Ca2 (dotted gray
line). c, L3055 cells were pretreated with goat F(ab)2 anti-human IgM ( chain-specific) overnight to remove
sIgM by capping and endocytosis (thin line). In parallel, there was a reduction in binding of MBL (thick line) to
that in the absence of Ca2 (dotted gray line). The filled histograms represent unlabeled cells.
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prior to the processing of complex structures. This allows the
glycans to retain a composition not generally found at the cell
surface. The Fab of both FL2 and FL3, which have three and two
potential N-glycosylation sites, respectively, in the V regions,
contained complex glycans in addition to the oligomannose,
suggesting that sites are differentially glycosylated according to
location. It is generally accepted that more exposed sites con-
tain more highly processed glycans; however, amino acid
sequence is also important, and the local three-dimensional
protein structure is a major factor in regulating the degree of
processing. For example, a study of the glycosylation of the
influenza A virus hemagglutinin (45) showed that the glycan
processing is site-specific and that one site that is buried in the
hemagglutinin trimer contained only oligomannose glycans.
The investigation of Thy-1 of rat brain and thymus (13) dem-
onstrated that there is both tissue- and site-specific glycosyla-
tion and that the processing of oligosaccharides at one site is
influenced by the glycosylation at other sites. A restriction in
the processing of complex sugars was observed previously in
the V regions of an artificially generated antibody expressed by
a mouse hybridoma. The natural antibody had an NYT motif
introduced at Asn58 in CDR2 of VH following somaticmutation
at position 60 (Asn to Thr). This site was glycosylated with
complex sugars. However, site-directedmutagenesis of Lys62 to
Thr resulted in the introduction of a new glycosylation site at
Asn60, which contained oligomannose glycans although the site
was on the exposed loop of CDR2 (46, 47).
Molecular modeling of the Fab of FLIgG and FLIgM has
revealed that, surprisingly, one or more glycosylation sites are
located within the antigen-binding region, which would be
expected to restrict the access of the processing enzymes. Gly-
can analysis has shown that the proportion of oligomannose
glycans in the HC is consistent with complete occupancy of the
antigen-binding regions in most cases. Where there is more
thanonepotential glycosylation site in theV region, these occur
both in the antigen-binding region and in more exposed posi-
tions. In FL2, when all the three potential sites are glycosylated,
the proportions of oligomannose and complex glycans are con-
sistent with two of the sites being occupied by oligomannose
glycans and the third site by complex glycans.
The GC is a site where antigen-stimulated B-cells are
selected or die, the decision being basedmainly on the strength
of antigen binding (48). Since sIg-negative tumors are rare,
tumors located in the GC may retain a requirement for the
engagement of sIg. FLIg bound to MBL, demonstrating
the exposure of diequatorial hydroxyl groups at C3 and C4 on
the terminal mannose (49) and indicating that C-type lectin
receptors (CLR) could be involved in FL. Indeed, MBL is pres-
ent on the surface of immature dendritic cells (DCs) (50). Other
cell surface candidates for binding the oligosaccharides include
mannose receptor, a CLR expressed onmacrophages, DCs, and
endothelium, and also endo 180, DEC-205, and DC-SIGN (51–
53). CLRs are highly expressed on immature DCs, and DC-
SIGN is expressed by DCs in lymphoid tissue and lymph nodes.
ADC subset has been found that localizes within B-cell follicles
(54). Interactions between the BL cell line L3055, which has
sugars located in the CDR, and a follicular DC line have been
shown to lead to the proliferation of L3055 cells (28). The nor-
mal function of the receptors of the innate immune system is to
bind to pathogens, but they can also bind endogenous and self-
ligands (53), suggesting a mechanism for the interaction of the
oligomannose glycans with cell surface lectins that provides a
substitute for antigen clustering.
The survival of patients with FL correlates with genes
expressed by nonmalignant immune GC cells that infiltrate
the tumor. Environmental signals from the GC cells, which
FIGURE 7.Molecular models of FL31 Fab domains showing VH glycosyla-
tion. Themolecule is shown in two orientations, side on (above) and looking
downon the antigen-binding site (below). Light blue, LC; dark blue, HC; yellow,
cysteines; orange, oligomannose glycans.
Mannose Sugars in Antigen-binding Site of FL sIg
MARCH 9, 2007•VOLUME 282•NUMBER 10 JOURNAL OF BIOLOGICAL CHEMISTRY 7413
include follicular dendritic cells and macrophages, appear to
promote survival or proliferation of malignant cells (55). It
cannot be ruled out that the infiltrating cells may also inter-
act with the oligomannose glycans on the surface of FL
B-cells. It is also possible that the new glycosylation sites may
alter local folding and domain structure, such that new pep-
tide epitopes may become accessible and contribute to anti-
gen-independent survival of FL B-cells.
The role of the oligomannose glycans is likely to be important
in the early stage of tumor growth and is an example of the
processes by which tumor cells adapt to and exploit hostile
environments. At later stages, further chromosomal transfor-
mations would be expected to allow wider dissemination of
tumor cells (8). In terms of therapy, the targeting of small mol-
ecules or antibodies to block the putative CLR interaction may
be effective at the early stage of disease. It is possible that the
highly effective treatment of lymphoma with anti-idiotypic
antibody directed at sIg could be acting in this way (17, 56, 57).
The unexpected finding that oligomannose sugars are
covalently bound within the antigen-binding region of FLIgs
opens up the possibility of novel therapeutic approaches toGC-
associated lymphomas.
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